There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 2 | 126 | 2283 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| Ask | Qty | Orders |
|---|---|---|
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
| 0 | 0 | 0 |
Annual Revenue,rose 8.92%, in the last year to ₹3,895.14 Cr. Its sector's average revenue growth for the last fiscal year was 10.77%.Annual Net Profit,rose 56.57% in the last year to ₹930.24 Cr. Its sector's average net profit growth for the last fiscal year was 36.82%.Return on Equity(ROE),for the last financial year was 47.67%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a leading biopharmaceutical company with a century-long presence in the country and is a subsidiary of GSK plc, U.K. It brings together science, technology and talent to prevent and treat disease through general medicines, specialty medicines and vaccines, reflecting a strong ‘Make in India, for India’ focus. The Company manufactures a wide range of general medicines locally, while vaccines and certain specialty medicines are imported, and is ranked No. 1 in the private vaccines market and No. 1 in dermatology, with seven brands featuring in the top 100 of the Indian Pharmaceuticals Market (IPM) . It operates a state-of-the-art manufacturing facility in Ambad, Nashik, and has an extensive distribution network covering 1,400+ towns across India .
Its business spans anti-infectives, pain management, dermatology, respiratory and hormones, and vaccines for adults and children. Notable brands cited in the report include Augmentin, Ceftum, Calpol, Eltroxin, Seretide, Trelegy Ellipta, Nucala and multiple vaccines across paediatric and adult indications . The Company served ~230 million patients in India in FY2024-25 and employs 3,100+ people nationwide .
GSK India has a registered office at GSK House, Worli, Mumbai, and celebrated its centenary year during FY2024-25, marking the Company’s 100th Annual Report . It has one subsidiary, consistent with consolidated reporting disclosures for Biddle Sawyer Limited as the wholly owned subsidiary of the Company . Revenues are primarily generated in India, with a smaller contribution from foreign countries.
– Market leadership in private vaccines and dermatology; seven GSK brands in the top 100 IPM brands .
– R. S. Karnad, Chairperson
– Bhushan Akshikar, Managing Director
– Juby Chandy, Whole-time Director and Chief Financial Officer
– Somasundaram PR, Audit Committee Chairman and Independent Director
– Board (Independent/Non-Executive): M. Anand; Dr. (Ms.) S. Maheshwari; Dr. A. Wadhawan; S. Williams
– Leadership Team: Carson Dalton (EVP, Communications and Government Affairs); Vibhuti Gupta (VP, Commercial Operations and Strategy); Rishikesh Jaiwant (EVP, Supply Chain Operations); Dr. Shalini Menon (EVP, Medical Affairs); Sharmishta Mitra (VP, Paediatric Vaccines); Ajay Nadkarni (VP, Real Estate, Administration and Company Secretary); Amit Pandey (EVP, Legal); Omkar Parnandiwar (VP, Adult Vaccines); Aparajita Rajput (VP, Technology); Chinmay Sharma (EVP, Human Resources); Dr. Simrat Sohal (VP, Ethics and Compliance) .
– Centenary celebrations included a symbolic bell ringing at BSE on November 12, 2024, a commemorative coffee table book, and a customised MyStamp and Special Cover released on January 4, 2025 .
– New launches: The Company is on track to launch Zejula (Niraparib) for ovarian cancer and Jemperli (Dostarlimab) for recurrent endometrial cancer as it expands into Oncology .
– Adult immunisation push: Shingrix (Herpes Zoster Vaccine Recombinant, Adjuvanted) adoption continued to rise alongside strengthened paediatric vaccine distribution .
– Digital engagement: Over 70 Per cent increase in total interactions with healthcare professionals through digital channels, including augmented reality for Augmentin and Google Rich Communication Services .
– Governance changes: Appointment of Independent Directors Somasundaram PR and Dr. A. Wadhawan with effect from March 26, 2025; re-appointment of Juby Chandy as Whole-time Director & CFO from April 1, 2025 .
The Company focuses on general medicines, specialty medicines and vaccines across therapy areas such as anti-infectives, respiratory, dermatology and pain management .
It operates across India with coverage in 1,400+ towns and runs a manufacturing facility in Ambad, Nashik, supported by a strong national distribution network .
